Integrin signaling and lung cancer

Cell Adhesion and Migration

Volumn 4, Issue 1, 2010, Pages 124-129

  Caccavari, Francesca ^a   Valdembri, Donatella ^a   Sandri, Chiara ^a   Bussolino, Federico ^a   Serini, Guido ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Fibronectin; Integrins; Lung cancer; Metastasis; Traffic

Indexed keywords

GROWTH FACTOR; INTEGRIN;

CANCER CLASSIFICATION; CELL ADHESION; CELL MIGRATION; LUNG NON SMALL CELL CANCER; METASTASIS; PROGNOSIS; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 77449143786     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.4161/cam.4.1.10976     Document Type: Review

References (67)

1. Yilmaz M, Christofori G, Lehembre F. Distinct mechanisms of tumor invasion and metastasis. Trends Mol Med 2007; 13:535-41.
2. Serini G, Valdembri D, Bussolino F. Integrins and angiogenesis: a sticky business. Exp Cell Res 2006; 312:651-8.
3. Weber C, Kitayama J, Springer TA. Differential regulation of beta1 and beta2 integrin avidity by chemoattractants in eosinophils. Proc Natl Acad Sci USA 1996; 93:10939-44.
4. Byzova TV, Goldman CK, Pampori N, Thomas KA, Bett A, Shattil SJ, Plow EF. A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Mol Cell 2000; 6:851-60.
5. Trusolino L, Serini G, Cecchini G, Besati C, Ambesi-Impiombato FS, Marchisio PC, De Filippi R. Growth factor-dependent activation of alphavbeta3 integrin in normal epithelial cells: implications for tumor invasion. J Cell Biol 1998; 142:1145-56.
6. Serini G, Valdembri D, Zanivan S, Morterra G, Burkhardt C, Caccavari F, et al. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 2003; 424:391-7.
7. Jones MC, Caswell PT, Norman JC. Endocytic recycling pathways: emerging regulators of cell migration. Curr Opin Cell Biol 2006; 18:549-57.
8. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004; 5:816-26.
9. Janes SM, Watt FM. New roles for integrins in squamous-cell carcinoma. Nat Rev Cancer 2006; 6:175-83.
10. Caswell P, Norman J. Endocytic transport of integrins during cell migration and invasion. Trends Cell Biol 2008; 18:257-63.
11. Caswell PT, Spence HJ, Parsons M, White DP, Clark K, Cheng KW, et al. Rab25 associates with alpha5beta1 integrin to promote invasive migration in 3D microenvironments. Dev Cell 2007; 13:496-510.
12. Ramirez F, Rifkin DB. Extracellular microfibrils: contextual platforms for TGFbeta and BMP signaling. Curr Opin Cell Biol 2009; 21:616-22.
13. Caswell PT, Chan M, Lindsay AJ, McCaffrey MW, Boettiger D, Norman JC. Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments. J Cell Biol 2008; 183:143-55.
14. Nguyen NM, Senior RM. Laminin isoforms and lung development: all isoforms are not equal. Dev Biol 2006; 294:271-9.
15. Margadant C, Frijns E, Wilhelmsen K, Sonnenberg A. Regulation of hemidesmosome disassembly by growth factor receptors. Curr Opin Cell Biol 2008; 20:589-96.
16. Litjens SH, de Pereda JM, Sonnenberg A. Current insights into the formation and breakdown of hemidesmosomes. Trends Cell Biol 2006; 16:376-83.
17. Kreidberg JA, Donovan MJ, Goldstein SL, Rennke H, Shepherd K, Jones RC, Jaenisch R. Alpha3beta1 integrin has a crucial role in kidney and lung organogenesis. Development 1996; 122:3537-47.
18. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008; 359:1367-80.
19. Astrof S, Hynes RO. Fibronectins in vascular morphogenesis. Angiogenesis 2009; 12:165-75.
20. Mao Y, Schwarzbauer JE. Fibronectin fibrillogenesis, a cell-mediated matrix assembly process. Matrix Biol 2005; 24:389-99.
21. Sakai T, Johnson KJ, Murozono M, Sakai K, Magnuson MA, Wieloch T, et al. Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. Nat Med 2001; 7:324-30.
22. Schafer M, Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol 2008; 9:628-38.
23. Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008; 452:633-7.
24. Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008; 452:638-42.
25. Zheng Y, Ritzenthaler JD, Roman J, Han S. Nicotine stimulates human lung cancer cell growth by inducing fibronectin expression. Am J Respir Cell Mol Biol 2007; 37:681-90.
26. Adachi M, Taki T, Higashiyama M, Kohno N, Inufusa H, Miyake M. Significance of integrin alpha5 gene expression as a prognostic factor in node-negative non-small cell lung cancer. Clin Cancer Res 2000; 6:96-101.
27. Han JY, Kim HS, Lee SH, Park WS, Lee JY, Yoo NJ. Immunohistochemical expression of integrins and extracellular matrix proteins in non-small cell lung cancer: correlation with lymph node metastasis. Lung Cancer 2003; 41:65-70.
28. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111:1710-7.
29. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9:274-84.
30. Citi S. Protein kinase inhibitors prevent junction dissociation induced by low extracellular calcium in MDCK epithelial cells. J Cell Biol 1992; 117:169-78.
31. Ivaska J, Whelan RD, Watson R, PJ P. PKC epsilon controls the traffic of beta1 integrins in motile cells. EMBO J 2002; 21:3608-19.
32. Ivaska J, Kermorgant S, Whelan R, Parsons M, Ng T, Parker PJ. Integrin-protein kinase C relationships. Biochem Soc Trans 2003; 31:90-3.
33. Ivaska J, Vuoriluoto K, Huovinen T, Izawa I, Inagaki M, Parker PJ. PKCepsilon-mediated phosphorylation of vimentin controls integrin recycling and motility. EMBO J 2005; 24:3834-45.45.
34. Ng T, Parsons M, Hughes WE, Monypenny J, Zicha D, Gautreau A, et al. Ezrin is a downstream effector of trafficking PKC-integrin complexes involved in the control of cell motility. EMBO J 2001; 20:2723-41.
35. Ng T, Shima D, Squire A, Bastiaens PI, Gschmeissner S, Humphries MJ, Parker PJ. PKCalpha regulates beta1 integrin-dependent cell motility through association and control of integrin traffic. EMBO J 1999; 18:3909-23.
36. Baxter G, Oto E, Daniel-Issakani S, Strulovici B. Constitutive presence of a catalytic fragment of protein kinase C epsilon in a small cell lung carcinoma cell line. J Biol Chem 1992; 267:1910-7.
37. Tuomi S, Mai A, Nevo J, Laine JO, Vilkki V, Ohman TJ, et al. PKCepsilon regulation of an alpha5 integrin-ZO-1 complex controls lamellae formation in migrating cancer cells. Sci Signal 2009; 2:32.
38. Rottner K, Hall A, Small JV. Interplay between Rac and Rho in the control of substrate contact dynamics. Curr Biol 1999; 9:640-8.
39. Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 2007; 19:124-34.
40. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358:1160-74.
41. Bellahcene A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS. Small integrinbinding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 2008; 8:212-26.
42. Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 2007; 57:373-80.
43. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-43.
44. Medico E, Gentile A, Lo Celso C, Williams TA, Gambarotta G, Trusolino L, Comoglio PM. Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth. Cancer Res 2001; 61:5861-8.
45. Sheppard D. Functions of pulmonary epithelial integrins: from development to disease. Physiol Rev 2003; 83:673-86.
46. Elayadi AN, Samli KN, Prudkin L, Liu YH, Bian A, Xie XJ, et al. A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res 2007; 67:5889-95.
47. Sheppard D. Roles of alphav integrins in vascular biology and pulmonary pathology. Curr Opin Cell Biol 2004; 16:552-7.
48. Wipff PJ, Rifkin DB, Meister JJ, Hinz B. Myofibroblast contraction activates latent TGFbeta1 from the extracellular matrix. J Cell Biol 2007; 179:1311-23.
49. Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H, et al. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 2005; 115:339-47.
50. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002; 3:349-63.
51. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006; 5:1597-601.
52. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/ CXCL12 secretion. Cell 2005; 121:335-48.
53. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998; 94:715-25.
54. Hinz B, Celetta G, Tomasek JJ, Gabbiani G, Chaponnier C. Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol Biol Cell 2001; 12:2730-41.
55. Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005; 8:241-54.
56. Butcher DT, Alliston T, Weaver VM. A tense situation: forcing tumour progression. Nat Rev Cancer 2009; 9:108-22.
57. Kilarski WW, Samolov B, Petersson L, Kvanta A, Gerwins P. Biomechanical regulation of blood vessel growth during tissue vascularization. Nat Med 2009; 15:657-64.
58. de Waal RM, Leenders WP. Sprouting angiogenesis versus co-option in tumor angiogenesis. EXS 2005; 65-76.
59. Hannigan G, Troussard AA, Dedhar S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer 2005; 5:51-63.
60. Legate KR, Montanez E, Kudlacek O, Fassler R. ILK, PINCH and parvin: the tIPP of integrin signalling. Nat Rev Mol Cell Biol 2006; 7:20-31.
61. Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci USA 1998; 95:11211-6.
62. Lynch DK, Ellis CA, Edwards PA, Hiles ID. Integrinlinked kinase regulates phosphorylation of serine 473 of protein kinase B by an indirect mechanism. Oncogene 1999; 18:8024-32. 63. Danial NN. BAD: undertaker by night, candyman by day. Oncogene 2008; 27:53-70.
63. McDonald PC, Fielding AB, Dedhar S. Integrin-linked kinase-essential roles in physiology and cancer biology. J Cell Sci 2008; 121:3121-32.
64. Christofori G. New signals from the invasive front. Nature 2006; 441:444-50.
65. Okamura M, Yamaji S, Nagashima Y, Nishikawa M, Yoshimoto N, Kido Y, et al. Prognostic value of integrin beta1-ILK-pAkt signaling pathway in non-small cell lung cancer. Hum Pathol 2007; 38:1081-91.
66. Takanami I. Increased expression of integrin-linked kinase is associated with shorter survival in non-small cell lung cancer. BMC Cancer 2005; 5:1.
67. Liu J, Costello PC, Pham NA, Pintillie M, Jabali M, Sanghera J, et al. Integrin-linked kinase inhibitor KP-392 demonstrates clinical benefits in an orthotopic human non-small cell lung cancer model. J Thorac Oncol 2006; 1:771-9.